Free Trial

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

$6.84
+0.08 (+1.18%)
(As of 06/28/2024 ET)

Ocular Therapeutix - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$15.83
131.48% Upside
High Forecast$22.00
Average Forecast$15.83
Low Forecast$11.00
TypeCurrent Forecast
7/1/23 to 6/30/24
1 Month Ago
6/1/23 to 5/31/24
3 Months Ago
4/2/23 to 4/1/24
1 Year Ago
7/1/22 to 7/1/23
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$15.83$15.17$16.80$12.50
Forecasted Upside131.48% Upside189.81% Upside145.61% Upside127.43% Upside

OCUL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

OCUL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Ocular Therapeutix Stock vs. The Competition

TypeOcular TherapeutixMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside131.48% Upside804.36% Upside11.52% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/21/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Bancroft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/21/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Amin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$15.00 ➝ $15.00+144.70%
6/14/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00+177.78%
5/8/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Outperform ➝ Market Outperform$24.00 ➝ $22.00+291.46%
2/9/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$15.00+198.21%
9/14/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$18.00+390.46%
New Government Policy to Wipe Out Seniors Wealth (Ad)

Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.

Click Here To Get Your FREE Guide Now!
11/8/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetStrong-Buy$29.00 ➝ $14.00+294.37%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:49 PM ET.

OCUL Forecast - Frequently Asked Questions

What is Ocular Therapeutix's stock forecast and purchase recommendation?

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Ocular Therapeutix is $15.83, with a high forecast of $22.00 and a low forecast of $11.00. The consensus rating for Ocular Therapeutix stock is Moderate Buy based on the current 1 hold rating and 5 buy ratings for OCUL. Learn more on OCUL's analyst rating history.

Do Wall Street analysts like Ocular Therapeutix more than its competitors?

Analysts like Ocular Therapeutix more than other "medical" companies. The consensus rating score for Ocular Therapeutix is 2.83 while the average consensus rating score for "medical" companies is 2.71. Learn more on how OCUL compares to other companies.

Is Ocular Therapeutix being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, Ocular Therapeutix's stock had 1 upgrade and 1 downgrade by analysts.

Does Ocular Therapeutix's stock price have much upside?

According to analysts, Ocular Therapeutix's stock has a predicted upside of 208.42% based on their 12-month stock forecasts.

What analysts cover Ocular Therapeutix?

Ocular Therapeutix has been rated by research analysts at HC Wainwright, JMP Securities, Piper Sandler, and TD Cowen in the past 90 days.


This page (NASDAQ:OCUL) was last updated on 6/30/2024 by MarketBeat.com Staff

From Our Partners